新生血管性年龄相关性黄斑变性眼内炎后的临床结局与治疗过程
该多中心回顾性系列研究评估了新生血管性年龄相关性黄斑变性(nAMD)患者在接受玻璃体腔注射治疗期间发生眼内炎后的临床过程。研究显示眼内炎后患者所需抗VEGF注射频率降低,13.3%的患眼nAMD变为静止,多数重新开始抗VEGF治疗者获得更好结局。
要点
- 眼内炎后nAMD患者抗VEGF注射间隔延长(7.4±0.61周 vs 11.5±1.8周,P=0.004)。
- 13.3%的患眼nAMD变为静止,22.7%的患者未再接受nAMD治疗。
- 眼内炎后第1周视力较好和重新开始nAMD治疗与最终视力较好相关。
核心结论
- nAMD患者发生眼内炎后所需注射次数减少,提示疾病活动性发生生物学改变。
- 13.3%的患眼nAMD变为静止,多数重新开始抗VEGF治疗者获得更好结局。
研究设计与样本
- 多中心、回顾性系列研究。
- 2013年4月至2018年10月期间共行196,598次玻璃体腔抗VEGF注射,发生75例眼内炎(发生率0.0381%)。
主要发现
- 玻璃体腔抗VEGF药物(P=0.29)、麻醉方法(P=0.26)、聚维酮浓度(P=0.22)或任何术中变量与眼内炎发生率无关联。
- 眼内炎消退后,17例患者(22.7%)未再接受nAMD治疗,其中10例因疾病不活动(随访115±8.4周)。
- 感染后患者所需抗VEGF注射频率降低(7.4±0.61周 vs 11.5±1.8周;P=0.004)。
- 感染前logMAR视力为0.585±0.053(约20/77),眼内炎时恶化至1.67±0.08(约20/935;P<0.001),眼内炎后治疗第1天再次恶化至1.94±0.064(数指;P<0.001),重新开始nAMD治疗后改善至1.02±0.11(约20/209;P<0.001)。
临床怎么用
- nAMD患者发生眼内炎后,应考虑疾病活动性可能降低,抗VEGF注射间隔可延长。
- 眼内炎消退后重新开始抗VEGF治疗与更好的最终视力相关。
- 眼内炎后第1周视力较好预示最终视力较好,链球菌培养阳性提示视力预后较差。
局限性
- 回顾性研究设计。
- 未报告眼内炎具体治疗方案对结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the clinical course of patients with neovascular age-related macular degeneration (nAMD) after developing endophthalmitis during their treatment with intravitreal injections. METHODS: Multicenter, retrospective series. RESULTS: From April 2013 to October 2018, 196,598 intravitreal anti-vascular endothelial growth factor (VEGF) injections were performed, with 75 cases of endophthalmitis (incidence 0.0381%). There was no association between intravitreal anti-VEGF drug (P = 0.29), anesthetic method (P = 0.26), povidone concentration (P = 0.22), or any intraprocedure variable and endophthalmitis incidence. Seventy-two patients (96%) were treated with intravitreal tap and inject , while 3 underwent immediate pars plana vitrectomy. After endophthalmitis resolution, 17 patients (22.7%) were not re-treated for nAMD (in 10 cases due to inactive disease; follow-up, 115 ± 8.4 weeks). Patients required less frequent anti-VEGF injections after infection (7.4 ± 0.61 weeks vs. 11.5 ± 1.8 weeks; P = 0.004). Preinfection logarithm of the minimum angle of resolution visual acuity was 0.585 ± 0.053 (∼20/77). It worsened with endophthalmitis (1.67 ± 0.08, ∼20/935; P < 0.001) and again on postendophthalmitis treatment day 1 (1.94 ± 0.064; count fingers; P < 0.001), but improved after reinitiating nAMD therapy (1.02 ± 0.11; ∼20/209; P < 0.001). Better visual acuity on postendophthalmitis week 1 (P = 0.002) and reinitiation of nAMD treatment (P = 0.008) were associated with better final visual acuity, and streptococcal culture with worse visual acuity (P = 0.028). The postendophthalmitis treatment interval was associated with the anti-VEGF drug used (aflibercept = ranibizumab > bevacizumab; P < 0.001). CONCLUSION: Patients with nAMD required fewer injections after endophthalmitis, suggesting a biological change in disease activity. Neovascular age-related macular degeneration became quiescent in 13.3% of eyes. Most achieved better outcomes with anti-VEGF reinitiation.
引用
- Koulisis N, Moysidis SN, Govindaraju VK, et al. CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITIS. Retina. 2021. PMID: 33079789. doi:10.1097/IAE.0000000000002998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。